Evidence map›Paper›PMID 41959794›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Mutation-specific impairment of TET2 and DNMT3A enzymatic activity predicts clonal hematopoiesis disease risk.

Yash Pershad, Kun Zhao, Joseph C Van Amburg, Robert W Corty, Alyssa C Parker, Alexander J Silver, Yara Almadani, Ashwin Kishtagari, Emily Hodges, Michael R Savona and 2 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yash PershadVanderbilt Genetics Institute, Nashville, TN, USA.ORCID 0000-0002-2282-1403
Kun ZhaoVanderbilt Genetics Institute, Nashville, TN, USA.
Joseph C Van AmburgVanderbilt Genetics Institute, Nashville, TN, USA.ORCID 0000-0002-1410-6995
Robert W CortyDivision of Rheumatology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-6787-9051
Alyssa C ParkerVanderbilt Genetics Institute, Nashville, TN, USA.ORCID 0000-0002-6632-7458
Alexander J SilverDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-8255-3140
Yara AlmadaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Ashwin KishtagariDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-1149-4571
Emily HodgesVanderbilt Genetics Institute, Nashville, TN, USA.ORCID 0000-0001-6513-610X
Michael R SavonaDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-3763-5504
J Brett HeimlichDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-2812-5326
Alexander G BickVanderbilt Genetics Institute, Nashville, TN, USA.ORCID 0000-0001-5824-9595

Funding

Clonal Hematopoiesis Aging Resiliency MechanismsR01AG088657 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Alexander Bick, Siddhartha Jaiswal · 2024 to 2026
$6.6M
Training Program on Genetic Variation and Human PhenotypesT32GM145734 · NIGMS · VANDERBILT UNIVERSITY · PI Jennifer Below, DAVID C SAMUELS · 2022 to 2026
$1.6M
Single Cell Foundation Model enabled drug discovery for clonal hematopoiesisUG3AG097155 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BICK, ALEXANDER, MADDURI, RAVI KIRAN · 2025 to 2025
$1.0M
Defining the cellular and molecular consequences in TET2 CHIPK08HL171833 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEIMLICH, JONATHAN BRETT · 2025 to 2025
$159k
Understanding dynamics and phenotypic consequences of clonal hematopoiesis caused by mosaic chromosomal alterationsF30AG099331 · NIA · VANDERBILT UNIVERSITY · PI Yash Pershad · 2026 to 2026
$36k
NHLBI NIH HHS K08 HL171833NIA NIH HHS F30 AG099331NIA NIH HHS R01 AG088657NIA NIH HHS UG3 AG097155NIGMS NIH HHS T32 GM145734
6 · The paper itself

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) driven by somatic mutations in TET2 and DNMT3A is present in >10% of adults over 60 and confers substantial risk for hematologic malignancy and cardiovascular disease, yet the majority of patients with CHIP do not progress to disease. Analyzing 1,020,538 individuals across three biobanks (UK Biobank, All of Us, BioVU), we show that a discrete subset of enzymatically disruptive mutations -

Identifiers

PMID41959794
PMCPMC13060411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.